Phase II Study of Continuous Dosing of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GISTs) After Failure of Imatinib and Sunitinib

Next Previous
Trial Profile

Phase II Study of Continuous Dosing of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GISTs) After Failure of Imatinib and Sunitinib

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use

    • Most Recent Events

    • 05 Feb 2018 Status changed from recruiting to completed.
    • 30 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 22 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top